Rezolute, Inc. (RZLT)
Largest Insider Buys in Sector
RZLT Stock Price History Chart
RZLT Stock Performance
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. …
Insider Activity of Rezolute, Inc.
Over the last 12 months, insiders at Rezolute, Inc. have bought $575,388 and sold $0 worth of Rezolute, Inc. stock.
On average, over the past 5 years, insiders at Rezolute, Inc. have bought $4.37M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Evans Daron (CFO) — $1.09M. ROBERTS BRIAN KENNETH (Chief Medical Officer) — $93,563. Kim Young-Jin (director) — $69,859.
The last purchase of 4,259 shares for transaction amount of $20,017 was made by Hogenhuis Wladimir (director) on 2024‑09‑24.
List of Insider Buy and Sell Transactions, Rezolute, Inc.
| 2024-09-24 | director | 4,259 0.0075% | $4.70 | $20,017 | +3.83% | |||
| 2024-06-25 | director | 4,815 0.01% | $4.15 | $19,982 | +21.71% | |||
| 2024-06-14 | Chief Medical Officer | 7,600 0.0139% | $3.91 | $29,743 | +18.99% | |||
| 2024-06-14 | CFO | 40,000 0.0754% | $4.04 | $161,568 | +18.99% | |||
| 2024-05-29 | CFO | 451 0.001% | $3.50 | $1,579 | +13.80% | |||
| 2024-05-24 | CFO | 2,942 0.0077% | $3.23 | $9,503 | +32.02% | |||
| 2024-05-23 | Chief Medical Officer | 7,500 0.0164% | $2.69 | $20,138 | +54.10% | |||
| 2024-05-23 | CFO | 58 0.0001% | $2.85 | $165 | +54.10% | |||
| 2024-03-28 | Chief Medical Officer | 500 0.0013% | $2.55 | $1,275 | +70.20% | |||
| 2024-03-15 | CFO | 20,000 0.048% | $1.69 | $33,830 | +140.17% | |||
| 2024-03-14 | Chief Medical Officer | 10,000 0.024% | $1.88 | $18,800 | +134.62% | |||
| 2024-03-08 | CFO | 50,000 0.1293% | $1.93 | $96,345 | +124.21% | |||
| 2024-03-07 | director | 36,503 0.0963% | $1.91 | $69,859 | +135.08% | |||
| 2024-03-07 | Chief Medical Officer | 500 0.0013% | $1.85 | $925 | +135.08% | |||
| 2024-02-26 | Chief Medical Officer | 2,000 0.0052% | $1.70 | $3,400 | +151.22% | |||
| 2024-02-26 | CEO | 5,000 0.0129% | $1.68 | $8,400 | +151.22% | |||
| 2024-02-23 | Chief Medical Officer | 6,000 0.015% | $1.69 | $10,140 | +138.95% | |||
| 2024-02-16 | CFO | 46,400 0.1132% | $1.31 | $60,576 | +196.30% | |||
| 2024-02-16 | Chief Medical Officer | 7,000 0.0171% | $1.31 | $9,142 | +196.30% | |||
| 2023-07-03 | Chief Medical Officer | 5,000 0.0091% | $1.90 | $9,500 | -27.90% |
Insider Historical Profitability
| Kim Young-Jin | director | 115450 0.2064% | $5.76 | 2 | 0 | |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 54352 0.0972% | $5.76 | 11 | 0 | <0.0001% |
| Hogenhuis Wladimir | director | 41767 0.0747% | $5.76 | 4 | 0 | <0.0001% |
| Evans Daron | CFO | 40000 0.0715% | $5.76 | 7 | 0 | |
| Elam Nevan C | CEO | 7817 0.014% | $5.76 | 1 | 0 |
Institutional Investor Ownership
| Federated Hermes | $25.89M | 19.76 | 10.15M | 0% | +$0 | 0.06 | |
| Nantahala Capital Management Llc | $7.71M | 5.88 | 3.02M | +96.59% | +$3.79M | 0.36 | |
| Vivo Capital | $7.13M | 5.45 | 2.8M | -13.73% | -$1.14M | 0.62 | |
| Affinity Asset Advisors | $4.08M | 3.11 | 1.6M | New | +$4.08M | 0.06 | |
| The Vanguard Group | $3.96M | 3.02 | 1.55M | +10.35% | +$371,535.04 | <0.0001 |